Abstracts tagged "Autoantibody(ies)"

Abstract Number: 1650 • ACR Convergence 2024
IL-33 Expands Plasma Cells, Disrupts Germinal Centers and Increases Autoantibody Production
Andre Limnander¹, Eva Conde¹, Seblewongel Asrat², Andrea Vecchione², Kaitlyn Gayvert², Paulina Pedraza², Carley Tasker², Sharon Huang², Dmitry Yarilin², Dylan Birchard², Li-Hong Ben², Wei Keat Lim², Andrew Murphy², Matthew Sleeman² and Jamie orengo¹, ¹Regeneron Pharmaceuticals, Tarrytown, NY, ²Regeneron Pharmaceuticals, Tarrytown
Background/Purpose: IL-33 is a pro-inflammatory cytokine that plays a role in asthma, COPD and autoimmune diseases. The role of IL-33 on B cell maturation and…
Abstract Number: 2053 • ACR Convergence 2024
Presence of ANA to Development of Rheumatic Diseases
Uyen Nguyen¹ and Huzaefah Syed², ¹Virginia Commonwealth University, School of Medicine, Richmond, VA, ²Virginia Commonwealth University Medical Center, Richmond, VA
Background/Purpose: One of the most common referrals seen in rheumatology is for a positive anti-nuclear antibody (ANA). Often, the referral does not yield in a…
Abstract Number: 2401 • ACR Convergence 2024
A Novel Modeling Approach to Elucidate the Role of Autoantibodies in Complement Activation in SLE
David Pisetsky¹, Yuankang Zhao², Matthew Engelhard³, Amanda Eudy⁴, Philip Tedeschi⁵, Alex Verdone⁵, Megan Clowse⁶, Lisa Criscione-Schreiber², Jayanth Doss³, Mithu Maheswaranathan², Rebecca Sadun³, Kai Sun³ and Jennifer Rogers², ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham, ³Duke University, Durham, NC, ⁴Duke University, Raleigh, NC, ⁵Immunovant, Inc, New York, NY, ⁶Duke University, Chapel Hill, NC
Background/Purpose: In SLE, ANAs can promote pathogenesis by forming immune complexes (ICs) that activate complement. While antibodies to DNA (anti-DNA) are known to be associated…
Abstract Number: 0049 • ACR Convergence 2024
Inflammatory Priming by Anti-MAA Antibodies in Rheumatoid Arthritis
Marcelo Afonso¹, Jitong Sun¹, Koji Sakuraba¹, Alexandra Circiumaru², Denis Lagutkin¹, Masa Filipovic¹, Anca Catrina¹, Caroline Grönwall¹, Aase Hensvold¹ and Bence Réthi¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm region, Stockholm, Sweden
Background/Purpose: We have previously shown that autoantibodies targeting malondialdehyde-acetaldehyde protein adducts (anti-MAA) in rheumatoid arthritis (RA) patients boosted osteoclast differentiation and induced bone erosion in mice…
Abstract Number: 0344 • ACR Convergence 2024
Characteristics of Patients with Antisynthetase Antibodies
Danny Kasto¹, Michael McLucas², Anne-Marie Aubin², Armando Faigl² and Gabor Major¹, ¹Dep of Rheumatology Royal Newcastle Centre / John Hunter Hospital, Rankin Park, New South Wales, Australia, ²Dep of Rheumatology Royal Newcastle Centre / John Hunter Hospital, Rankin Park, Australia
Background/Purpose: Aminoacyl transfer RNA synthetase antibodies (ASAbs) are associated with a range of clinical manifestations, including severe lung and muscle disease and are postulated to…
Abstract Number: 0838 • ACR Convergence 2024
The Mechanistic Impact of IgA anti-beta-2 Glycoprotein I on Accelerated Atherosclerosis in Primary APS
Kavya Sugur¹, Emily Chong¹, Srilakshmi Yalavarthi², Katarina Kmetova³, Lyndsay Kluge¹, Wenying Liang², Cyrus Sarosh⁴, NaveenKumar Somanathapura K², Jacqueline Madison², Ajay Tambralli², Jason Knight² and Yu Zuo², ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ⁴University of Michigan, Temperance, MI
Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease characterized by persistent antiphospholipid antibodies (aPL). APS patients experience significant morbidity and mortality, much of which…
Abstract Number: 1427 • ACR Convergence 2024
Observed and Simulated Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Fully Human FcRn Blocking Monoclonal Antibody, in Adults with Sjögren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study
Sophia G. Liva¹, fudan Zheng¹, Jocelyn H. Leu², Kathy Sivils³, Keying Ma¹, He Li⁴, Steven Leonardo⁵, Kim Lo¹, Jada Idokogi¹, Kim Campbell¹ and Jonathan J. Hubbard¹, ¹Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, ²Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA, ³Johnson & Johnson Innovative Medicine, Edmond, OK, ⁴Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, ⁵Janssen Research & Development, LLC, a Johnson & Johnson Company, Cambridge, MA
Background/Purpose: Sjögren’s disease (SjD) is a chronic, progressive autoimmune disease characterized by aberrant B lymphocyte activity, elevated IgG production, and the presence of IgG autoantibodies…
Abstract Number: 1652 • ACR Convergence 2024
Extracellular Vesicles from Lymphocyte B and Neutrophil Presents Ro52, Ro60 and La Autoantigens in Patient Suffering from Sjögren Syndrome
Lily BRUYERE¹, Anne-Claire DUCHEZ², Martin KILLIAN³ and Stéphane PAUL⁴, ¹université jean-monnet, saint-etienne, ²EFS, saint-etienne, ³chu Saint-Etienne, saint-etienne, ⁴CIRI, Saint Etienne, France
Background/Purpose: Extracellular Vesicles (EVs) are double lipid bilayer-enclosed membranous vesicles, produced and discharged from almost all cells. EVs are known for inter-cellular communication by releasing…
Abstract Number: 2058 • ACR Convergence 2024
Association of Anti-Synthetase Antibody Subtypes with Radiographic Progression of Interstitial Lung Disease in Anti-Synthetase Syndrome: An Analysis of the CLASS Project Database
Daphne Rivero Gallegos¹, Francisca Bozan², Sangmee Bae³, Giovanni Zanframundo⁴, Sara Faghihi-Kashani⁵, Iazsmin Bauer Ventura⁶, Eduardo Dourado⁷, Gianluca sambataro⁸, Akira Yoshida⁹, Tamera J Corte¹⁰, Francesco Bonella¹¹, Tracy J Doyle¹², david fiorentino¹³, Miguel Angel Gonzalez-Gay¹⁴, marie Hudson¹⁵, Masataka Kuwana¹⁶, Antonella Notarnicola¹⁷, Andrew Mammen¹⁸, Neil McHugh¹⁹, Frederick Miller²⁰, Carlomaurizio Montecucco²¹, Chester Oddis²², Jorge Rojas-Serrano²³, Jens Schmidt²⁴, Carlo A. Scire²⁵, Albert Selva-O’Callaghan²⁶, Victoria Werth²⁷, Rohit Aggarwal²⁸ and Lorenzo Cavagna²⁹, and CLASS project participating investigators, ¹INER, Ciudad de México, Mexico State, Mexico, ²Hospital Clinico Universidad de Chile, Santiago, Chile, ³UCLA, Los Angeles, CA, ⁴Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Milano, Italy, ⁵Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, San Francisco, CA, ⁶University of Chicago, Chicago, IL, ⁷Unidade Local de Saúde da Região de Aveiro, Aveiro, Portugal, ⁸University of Catania, Catania, Italy, ⁹Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, ¹⁰Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia, ¹¹Center for interstitial and rare lung diseases, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ¹²Brigham and Women's Hospital, West Roxbury, MA, ¹³Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA, ¹⁴University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ¹⁵McGill University, Montreal, QC, Canada, ¹⁶Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹⁷Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ¹⁸NIH, Bethesda, MD, ¹⁹University of Bath, Bath, United Kingdom, ²⁰NIH, NIEHS, Chapel Hill, NC, ²¹IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ²²Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²³National Institute of Respiratory Diseases, Ismael Cosío Villegas, Mexico City, Mexico, ²⁴University Medical Center Goettingen, Göttingen, Germany, ²⁵University of Milano Bicocca, Milan, Italy, ²⁶Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, ²⁷University of Pennsylvania, Wynnewood, PA, ²⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ²⁹University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy
Background/Purpose: In anti-synthetase syndrome (ASSD), clinical presentations vary from isolated interstitial lung disease (ILD) to systemic multi-organ manifestations. Several studies emphasize the crucial role of…
Abstract Number: 2443 • ACR Convergence 2024
The Clinical Phenotype of Anti-Th/To+ Patients in Systemic Sclerosis: A Case-control Study Within the European Scleroderma Trials and Research (EUSTAR) Cohort
Liala Moschetti¹, Eleonora Pedretti², Francesco Bonomi³, María Martín López⁴, Fabio Cacciapaglia⁵, cristiana sieiro santos⁶, Gianluca Moroncini⁷, Yannick Allanore⁸, Joana Caetano⁹, Brigitte Granel¹⁰, Laura Groseanu¹¹, Maria De Santis¹², Masataka Kuwana¹³, Veronica Codullo¹⁴, Mariana Pereira Silva¹⁵, Pietro Bearzi¹⁶, Laura Belloli¹⁷, Alida Taberner-Cortés¹⁸, Cristina Maglio¹⁹, Francesco Del Galdo²⁰, Corrado Campochiaro²¹, Marie-Elise Truchetet²², Giovanna Cuomo²³, Magda Parvu²⁴, Florenzo Iannone²⁵, Patricia Carreira²⁶, Serena Guiducci²⁷, Franco Franceschini¹, Paolo Airò¹ and Maria-Grazia Lazzaroni¹, ¹Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ²Scleroderma Unit, Rheumatology Unit, ERN ReCONNET, ASST Spedali Civili and University of Brescia; Italy, Brescia, Italy, ³Division of Rheumatology, Scleroderma Unit, University of Florence, AOU Careggi Firenze; Italy, Firenze, Italy, ⁴General University Hospital of Ciudad Real, Ciudad de México, Spain, ⁵Rheumatology Unit � DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ⁶Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁷Marche Polytechnic University, Ancona, Italy, ⁸Rheumatology department, Université Paris Cité, Cochin Hospital of Paris; France, Paris, France, ⁹Systemic Autoimmune Diseases Unit, Fernando Fonseca Hospital, Amadora; Portugal, Amadora, Portugal, ¹⁰Service de Médecine Interne Hôpital Nord de Marseille; France, Marseille, France, ¹¹Spitalul Sfanta Maria, Bucharest, Romania, ¹²Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital and Biomedical Sciences, Hu-manitas University, Milan; Italy, Milan, Italy, ¹³Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹⁴Unit of Rheumatology, San Matteo Hospital, Pavia, Italy, ¹⁵Rheumatology Department, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa; Portugal, Lisboa, Portugal, ¹⁶Immunorheumatology Unit, Università Campus Bio-Medico University of Roma; Italy, Roma, Italy, ¹⁷Niguarda Hospital, Milan, Milan, Italy, ¹⁸Hospital Universitario Doctor Peset, Valencia, Spain, ¹⁹University of Gothenburg, Gothenburg, Sweden, ²⁰University of Leeds, Leeds, United Kingdom, ²¹IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ²²Bordeaux University Hospital, Bordeaux, France, ²³Università degli studi della Campania Luigi Vanvitelli, Napoli, Italy, ²⁴Colentina Clinical Hospital, Rheumatology Department, Bucharest; Romania, Bucharest, Romania, ²⁵Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ²⁶Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, ²⁷Division of Rheumatology, Scleroderma Unit, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Background/Purpose: To evaluate clinical associations of anti-Th/To antibodies in SSc patients in a multicentre international cohort, focusing on interstitial lung disease (ILD), pulmonary arterial hypertension…
Abstract Number: 0064 • ACR Convergence 2024
Anti-Citrullinated Protein Antibodies Arise During Affinity Maturation of Germline-Encoded Antibodies to Carbamylated Proteins in Rheumatoid Arthritis
Marta Escarra-Senmarti¹, Michael Chungyoun², Dylan Ferris¹, Jeffrey Gray² and Felipe Andrade³, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²The Johns Hopkins Whiting School of Engineering, Baltimore, MD, ³The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: The production of antibodies to modified self-antigens is a hallmark in rheumatoid arthritis (RA). Antibodies to citrullinated (ACPAs) and carbamylated proteins (CarP) are of…
Abstract Number: 0346 • ACR Convergence 2024
Clonally Expanded and Total B Cells in Patients with Idiopathic Inflammatory Myopathies Show Skewed B Cell Subset Distribution and Reduced Somatic Hypermutation Relative to Healthy Controls
Amelia Sawyers¹, Leslie Crofford², Erin Wilfong³ and Rachel Bonami³, ¹Vanderbilt University School of Medicine, Nashville, TN, ²Vanderbilt University Medical Center, Melbourne, AR, ³Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a collection of rare, systemic rheumatic diseases. A role for B cells in IIM is indicated by the success…
Abstract Number: 0839 • ACR Convergence 2024
Comprehensive Single-cell Analysis Reveals Interferon Pathway Activation and Aberrant B Cell Dynamics in APS Autoimmunity
Haoyu Pan, Xiaohan Wei, Jinyi Qian, Shuyi Yu, Zhixia Yang, Zetao Ding, Chengde Yang and Hui Shi, Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic)
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized with the presence of pathogenic antiphospholipid antibodies (aPL) by autoreactive B cells. However, it remains…
Abstract Number: 1488 • ACR Convergence 2024
Clinical Utility and Performance of Anti-C1q Antibodies for Systemic Lupus Erythematosus: Comparative Analysis of Three Different Assays
Mariana Gonzalez-Trevino¹, MeLea Hetrick¹, Alain Sanchez-Rodriguez², Ali Duarte-Garcia¹ and Anne Tebo³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
Background/Purpose: SLE is an autoimmune disorder characterized by autoantibody-mediated tissue damage. Antibodies against C1q (anti-C1q) can identify patients with LN and rising titers predict renal…
Abstract Number: 1684 • ACR Convergence 2024
Autoantibodies to Transcription Factor a Mitochondria Are Associated with Damage Accrual, Malignancy Risk and Mortality in SLE
Eduardo Gomez¹, Daniel Goldman², Merlin Paz³, Michelle Petri² and Felipe Andrade⁴, ¹The Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³Johns Hopkins Medicine, Baltimore, MD, ⁴The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: We recently identified autoantibodies in SLE that target transcription factor A mitochondrial (TFAM), a critical protein in mitochondrial DNA transcription and packaging1. These autoantibodies…

« Previous Page
1
…
3
4
5
6
7
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].